Related Experiment Video

Updated: Jul 15, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

New technologies and therapies in the management of diabetes

Curtis L Triplitt1

  • 1University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229-3900, USA. curtis.triplitt@uhs-sa.com

The American Journal of Managed Care
|April 10, 2007
PubMed

Insights

Secondary failure affects 5-10% of type 2 diabetes patients. New therapies targeting incretin pathways and advanced insulins offer improved glycemic control and potential cost benefits.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes pharmacotherapy faces secondary failure in 5-10% of patients.
  • Understanding limitations of current treatments is crucial for effective diabetes management.
  • Factors contributing to secondary failure include declining beta cell function and lifestyle changes.

Purpose of the Study:

  • To review current therapeutic limitations in type 2 diabetes.
  • To explore the impact of novel pharmacotherapeutic agents.
  • To highlight the significance of non-glycemic effects and emerging treatment options.

Main Methods:

  • Literature review of current type 2 diabetes pharmacotherapies.
  • Analysis of factors contributing to secondary treatment failure.
  • Examination of recent advancements in diabetes treatment, including incretin-based therapies and new insulin formulations.

Main Results:

  • Secondary failure in type 2 diabetes is multifactorial.
  • Emerging therapies offer potential advantages beyond glycemic control.
  • Incretin mimetics and novel insulins represent significant therapeutic advancements.

Conclusions:

  • New therapeutic strategies, including incretin-based treatments and advanced insulins, show promise for managing type 2 diabetes.
  • Consideration of non-glycemic effects is important for long-term cost-effectiveness and patient outcomes.
  • Further research into these novel agents is warranted to optimize type 2 diabetes care.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...